Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 15/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RHOC | P08134 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22130452 | 1.00 | RHOA (0.58) | RHOALMNAPOLBHPGDMEN1 | |
| SCHEMBL22130453 | 0.94 | RHOA (0.52) | RHOALMNAPOLBHPGDMEN1 | |
| SCHEMBL22130461 | 0.94 | RHOA (0.52) | RHOALMNAPOLBHPGDMEN1 | |
| SCHEMBL20562068 | 0.83 | MEN1 (0.56) | RHOALMNAPOLBMEN1KMT2A | |
| SCHEMBL20562066 | 0.83 | MEN1 (0.56) | RHOALMNAPOLBMEN1KMT2A | |
| SCHEMBL22130454 | 0.83 | MEN1 (0.56) | RHOALMNAPOLBMEN1KMT2A | |
| SCHEMBL22130457 | 0.79 | L3MBTL1 (0.57) | RHOALMNAMEN1KMT2A | |
| SCHEMBL22130458 | 0.79 | L3MBTL1 (0.57) | RHOALMNAMEN1KMT2A | |
| SCHEMBL22130456 | 0.79 | LMNA (0.43) | LMNAPOLBHPGD | |
| SCHEMBL20562239 | 0.76 | RBP4 (0.40) | LMNAPOLBHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10688080-B2 | Compositions, methods of use, and methods of treatment | LIPA, LCT, GAA | RHOA 203/4885LMNA 338/4885POLB 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.